Catalent U.K. Swindon Zydis Ltd.

Primary study objective: To compare the efficacy of rimegepant versus placebo for the preventive treatment of migraine by evaluating the mean reduction in monthly migraine days during the entire double-blind treatment period compared to the observation period.

The efficacy of rimegepant compared with placebo in the acute treatment of migraine was assessed by measuring the co-primary endpoints of pain freedom 2 hours after dosing and freedom from the most bothersome migraine-related symptom (MBS).

Primary objective: To confirm the efficacy of dust mite allergen sublingual tablets compared with placebo for the treatment of nasal symptoms of dust mite allergic rhinitis as measured during the EEC at Week 24. Key secondary objectives: To confirm the efficacy of dust mite allergen sublingual tablets compared with placebo for the treatment of dust mite allergic rhinitis with or without conjunctivitis as measured during the EEC at Week 24. Safety objective: To evaluate the safety and tolerability of dust mite allergen sublingual tablets compared with placebo during the 24-week treatment period.